Free Trial

BellRing Brands (BRBR) Competitors

$57.30
-0.11 (-0.19%)
(As of 05/20/2024 ET)

BRBR vs. BIO.B, VKTX, CERE, LEGN, PEN, PCVX, BIO, ASND, ELAN, and GMED

Should you be buying BellRing Brands stock or one of its competitors? The main competitors of BellRing Brands include Bio-Rad Laboratories (BIO.B), Viking Therapeutics (VKTX), Cerevel Therapeutics (CERE), Legend Biotech (LEGN), Penumbra (PEN), Vaxcyte (PCVX), Bio-Rad Laboratories (BIO), Ascendis Pharma A/S (ASND), Elanco Animal Health (ELAN), and Globus Medical (GMED). These companies are all part of the "medical" sector.

BellRing Brands vs.

Bio-Rad Laboratories (NYSE:BIO.B) and BellRing Brands (NYSE:BRBR) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

In the previous week, BellRing Brands had 10 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 10 mentions for BellRing Brands and 0 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 1.09 beat BellRing Brands' score of 0.00 indicating that BellRing Brands is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Rad Laboratories Neutral
BellRing Brands Positive

Bio-Rad Laboratories has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, BellRing Brands has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.

BellRing Brands has a consensus price target of $61.83, indicating a potential upside of 7.91%. Given Bio-Rad Laboratories' higher probable upside, analysts clearly believe BellRing Brands is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
BellRing Brands
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.75

BellRing Brands has lower revenue, but higher earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than BellRing Brands, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.67B2.99-$637.32M-$10.36-27.02
BellRing Brands$1.67B4.48$165.50M$1.4439.79

Bio-Rad Laboratories received 10 more outperform votes than BellRing Brands when rated by MarketBeat users. However, 67.25% of users gave BellRing Brands an outperform vote while only 57.60% of users gave Bio-Rad Laboratories an outperform vote.

CompanyUnderperformOutperform
Bio-Rad LaboratoriesOutperform Votes
125
57.60%
Underperform Votes
92
42.40%
BellRing BrandsOutperform Votes
115
67.25%
Underperform Votes
56
32.75%

0.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 95.0% of BellRing Brands shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 0.8% of BellRing Brands shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BellRing Brands has a net margin of 10.39% compared to BellRing Brands' net margin of -12.37%. BellRing Brands' return on equity of 3.59% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories-12.37% 3.59% 2.55%
BellRing Brands 10.39%-70.95%29.97%

Summary

BellRing Brands beats Bio-Rad Laboratories on 13 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BRBR vs. The Competition

MetricBellRing BrandsFood & kindred products IndustryMedical SectorNYSE Exchange
Market Cap$7.49B$16.64B$5.04B$18.08B
Dividend YieldN/A3.49%44.98%3.43%
P/E Ratio39.798.83119.5021.97
Price / Sales4.482.532,490.7110.64
Price / Cash36.6712.6832.5515.96
Price / Book-23.294.175.025.18
Net Income$165.50M$722.59M$103.24M$974.43M
7 Day Performance-4.32%5.84%1.03%0.73%
1 Month Performance6.15%13.97%5.75%6.56%
1 Year Performance61.64%1.05%7.36%23.64%

BellRing Brands Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIO.B
Bio-Rad Laboratories
0 of 5 stars
$279.91
flat
N/A-25.1%$7.98B$2.67B-27.027,900
VKTX
Viking Therapeutics
4.3972 of 5 stars
$72.50
+0.2%
$112.25
+54.8%
+193.9%$7.99BN/A-77.9628
CERE
Cerevel Therapeutics
0.471 of 5 stars
$42.24
+0.4%
$42.67
+1.0%
+29.5%$7.67BN/A0.00334News Coverage
LEGN
Legend Biotech
2.3812 of 5 stars
$44.38
+3.3%
$82.64
+86.2%
-34.8%$8.07B$285.14M-29.991,800
PEN
Penumbra
4.8706 of 5 stars
$208.73
+1.9%
$300.64
+44.0%
-36.6%$8.09B$1.06B88.074,200
PCVX
Vaxcyte
0.1845 of 5 stars
$67.33
+2.5%
$78.50
+16.6%
+57.4%$7.32BN/A-15.73254
BIO
Bio-Rad Laboratories
4.689 of 5 stars
$294.05
+3.0%
$461.00
+56.8%
-23.6%$8.39B$2.67B-28.388,030
ASND
Ascendis Pharma A/S
1.1019 of 5 stars
$124.82
-5.5%
$173.88
+39.3%
+33.9%$7.27B$288.08M-12.99879High Trading Volume
ELAN
Elanco Animal Health
2.8483 of 5 stars
$17.07
+0.4%
$18.29
+7.1%
+99.8%$8.44B$4.42B-6.449,300
GMED
Globus Medical
4.481 of 5 stars
$62.87
-1.4%
$66.50
+5.8%
+18.0%$8.51B$1.57B98.245,000Analyst Upgrade

Related Companies and Tools

This page (NYSE:BRBR) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners